Cargando…

External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26

PURPOSE: To assess feasibility and safety of conventionally fractionated radiotherapy (cfRT) in patients with hepatocellular carcinoma (HCC). METHODS: Patients with histologically confirmed stage cT1-4, cN0-1 HCC and Child-Pugh Score (CPS) A or B disease were included in a phase I multicenter trial....

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Evelyn, Naehrig, Diana, Sassowsky, Manfred, Bigler, Martin, Buijsen, Jeroen, Ciernik, Ilja, Zwahlen, Daniel, Pellanda, Alessandra Franzetti, Meister, Andreas, Brauchli, Peter, Berardi, Simona, Kuettel, Erika, Dufour, Jean-François, Aebersold, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237353/ https://www.ncbi.nlm.nih.gov/pubmed/28086942 http://dx.doi.org/10.1186/s13014-016-0745-0

Ejemplares similares

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
por: Gargiulo, Piera, et al.
Publicado: (2019)

Enabling Secure XMPP Communications in Federated IoT Clouds Through XEP 0027 and SAML/SASL SSO
por: Celesti, Antonio, et al.
Publicado: (2017)

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022)

The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
por: Clough-Gorr, Kerri M, et al.
Publicado: (2013)

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)
por: Ghadjar, Pirus, et al.
Publicado: (2015)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †
por: Genta, Sofia, et al.
Publicado: (2022)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
por: Pestalozzi, Bernhard C., et al.
Publicado: (2017)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study
por: Tzankov, Alexandar, et al.
Publicado: (2015)

Visualization of the tumor cavity after lumpectomy of breast cancer for postoperative radiotherapy
por: Ciernik, Ilja F., et al.
Publicado: (2018)

Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions
por: Ghadjar, Pirus, et al.
Publicado: (2012)

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
por: Vetter, Marcus, et al.
Publicado: (2022)

Hierarchical enhanced non‐rigid registration for target volume correction and propagation for adaptive external beam radiotherapy of carcinoma of the prostate
por: Andronache, Adrian, et al.
Publicado: (2013)

Computing for Engineers and scientists with Fortran 77
por: McCracken, Daniel D.
Publicado: (1988)

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019)

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
por: Mark, Michael, et al.
Publicado: (2019)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

EXM 92-07 07/05/92
por: Daems, G
Publicado: (1992)

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

PAC investigation of$^{77}$Br $\rightarrow ^{77}$Se on silicon surfaces
por: Lohmüller, J, et al.
Publicado: (1995)

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
por: Blum, David, et al.
Publicado: (2012)

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019)

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
por: Joerger, Markus, et al.
Publicado: (2022)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023)

Fortran 77 : Principles of programming /
por: Wagener, Jerrold L.
Publicado: (1980)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
por: Rochlitz, Christoph, et al.
Publicado: (2016)

SHARE 77 Conference
Publicado: (1991)

Microcomputer '77 Conference
por: Collective
Publicado: (1977)

Effective Fortran 77
por: Metcalf, Michael
Publicado: (1985)

Essentials of FORTRAN 77
por: Shelley, John
Publicado: (1984)

Contents of volume 77
Publicado: (2008)

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
por: Eppenberger-Castori, Serenella, et al.
Publicado: (2020)

Intensity‐modulated radiotherapy and volumetric‐modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy
por: Krayenbuehl, Jerome, et al.
Publicado: (2013)

77th Annual International Meeting of the Psychometric Society
por: Millsap, Roger, et al.
Publicado: (2013)

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
por: Drexler, Beatrice, et al.
Publicado: (2019)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ba8ucej3lejnplh8pvg3961fie